NCT00606645View on ClinicalTrials.gov

Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Hodgkin LymphomaAnaplastic Large Cell Lymphoma
Interventions
BIOLOGICAL

XmAb2513

Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

43210

Ohio State University, Columbus

60612

Rush University Medical Center, Chicago

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

Xencor, Inc.

INDUSTRY

NCT00606645 - Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma | Biotech Hunter | Biotech Hunter